While some have argued that Benitec is too immature in its clinical/commercial pathway to command a high market cap, no-one told AveXis that story. In a tale that we all hoped that we could tell about Benitec, AveXis, which IPO'ed six months ago based on a Pl study, now has almost reached a $1B valuation.
How does that ad for super go? "Compare the pair" or something like that.
While some have argued that Benitec is too immature in its...
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)